bortezomib + melphalan + dexamethasone

Bortezomib + melphalan + dexamethasone is a three-drug combination regimen used primarily in the treatment of newly diagnosed systemic light-chain (AL) amyloidosis and multiple myeloma. Bortezomib is a proteasome inhibitor that disrupts protein degradation, leading to apoptosis in malignant plasma cells. Melphalan is an alkylating agent that crosslinks DNA, inhibiting replication and transcription, while dexamethasone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties. The combination has demonstrated improved hematologic response rates and overall survival compared to melphalan plus dexamethasone alone in AL amyloidosis, establishing it as a new standard of care for this indication[1][2]. It is also widely used off-label or as part of standard regimens for multiple myeloma.

Other names

bmdex